CKDXFOpthea Limited

About Opthea Limited (CKDXF)

Opthea Limited (CKDXF) is a Biotechnology company headquartered in New York, NY, United States whose shares trade over-the-counter on the Pink tier.

Opthea Limited is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD). Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients.

CKDXF key facts

Ticker symbol

CKDXF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

New York, NY, United States

Country of incorporation

AU

Year of incorporation

1984

Employees

11

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

6/30

Opthea Limited leadership

• Megan Baldwin — CEO, Managing Director
• Mike Tonroe — Secretary, CFO

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with C